BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol. 2014;9:881-888. [PMID: 24721888 DOI: 10.2215/cjn.02650313] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Sorohan BM, Ismail G, Andronesi A, Micu G, Obrișcă B, Jurubiță R, Sinescu I, Baston C. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol 2019;20:276. [PMID: 31337351 DOI: 10.1186/s12882-019-1463-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mahnensmith RL. Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2014;9:831-6. [PMID: 24721886 DOI: 10.2215/CJN.02480314] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
3 Fantus D, Rogers NM, Grahammer F, Huber TB, Thomson AW. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol 2016;12:587-609. [PMID: 27477490 DOI: 10.1038/nrneph.2016.108] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 14.2] [Reference Citation Analysis]
4 Nikonova AS, Deneka AY, Eckman L, Kopp MC, Hensley HH, Egleston BL, Golemis EA. Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Front Oncol 2015;5:228. [PMID: 26528438 DOI: 10.3389/fonc.2015.00228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
5 Akoh JA. Current management of autosomal dominant polycystic kidney disease. World J Nephrol 2015; 4(4): 468-479 [PMID: 26380198 DOI: 10.5527/wjn.v4.i4.468] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
6 Li Q, Wang Y, Deng W, Liu Y, Geng J, Yan Z, Li F, Chen B, Li Z, Xia R, Zeng W, Liu R, Xu J, Xiong F, Wu CL, Miao Y. Heterogeneity of cell composition and origin identified by single-cell transcriptomics in renal cysts of patients with autosomal dominant polycystic kidney disease. Theranostics 2021;11:10064-73. [PMID: 34815804 DOI: 10.7150/thno.57220] [Reference Citation Analysis]
7 Gui Y, Dai C. mTOR Signaling in Kidney Diseases. Kidney360 2020;1:1319-27. [DOI: 10.34067/kid.0003782020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 LaRiviere WB, Irazabal MV, Torres VE. Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl Res 2015;165:488-98. [PMID: 25438190 DOI: 10.1016/j.trsl.2014.11.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
9 Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, Maeda H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway. Toxins 2021;13:909. [DOI: 10.3390/toxins13120909] [Reference Citation Analysis]
10 Sharma K, Caroli A, Quach LV, Petzold K, Bozzetto M, Serra AL, Remuzzi G, Remuzzi A. Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One 2017;12:e0178488. [PMID: 28558028 DOI: 10.1371/journal.pone.0178488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Riegersperger M, Herkner H, Sunder-Plassmann G. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. Trials 2015;16:182. [PMID: 25899445 DOI: 10.1186/s13063-015-0692-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
12 Li A, Fan S, Xu Y, Meng J, Shen X, Mao J, Zhang L, Zhang X, Moeckel G, Wu D, Wu G, Liang C. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. J Cell Mol Med 2017;21:1619-35. [PMID: 28244683 DOI: 10.1111/jcmm.13091] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
13 Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clin J Am Soc Nephrol 2016;11:785-94. [PMID: 26912555 DOI: 10.2215/CJN.09900915] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
14 Kühn WE, Walz G. The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch Arztebl Int 2015;112:884-90. [PMID: 26900155 DOI: 10.3238/arztebl.2015.0884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
15 Slaats GG, Lilien MR, Giles RH. Nephronophthisis: should we target cysts or fibrosis? Pediatr Nephrol 2016;31:545-54. [PMID: 26219413 DOI: 10.1007/s00467-015-3162-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
16 Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev 2015;:CD010294. [PMID: 26171904 DOI: 10.1002/14651858.CD010294.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
17 Madhivanan K, Ramadesikan S, Hsieh WC, Aguilar MC, Hanna CB, Bacallao RL, Aguilar RC. Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins. Hum Mol Genet 2020;29:1700-15. [PMID: 32391547 DOI: 10.1093/hmg/ddaa086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Chebib FT, Torres VE. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 2018;13:1765-76. [PMID: 30049849 DOI: 10.2215/CJN.03960318] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
19 Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, Walz G, Zhou J, Yu AS. The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees. J Am Soc Nephrol 2015;26:2081-95. [PMID: 25952256 DOI: 10.1681/ASN.2014121192] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
20 Lin CH, Chao CT, Wu MY, Lo WC, Lin TC, Wu MS. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Int Urol Nephrol 2019;51:2015-25. [PMID: 31578673 DOI: 10.1007/s11255-019-02292-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Aboudehen K, Farahani S, Kanchwala M, Chan SC, Avdulov S, Mickelson A, Lee D, Gearhart MD, Patel V, Xing C, Igarashi P. Long noncoding RNA Hoxb3os is dysregulated in autosomal dominant polycystic kidney disease and regulates mTOR signaling. J Biol Chem 2018;293:9388-98. [PMID: 29716997 DOI: 10.1074/jbc.RA118.001723] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]